Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

BACKGROUND: Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunotherapies, including therapy half-life and persistenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardell, Jennifer L, Matsumoto, Lisa R, Chinn, Harrison, DeGolier, Kole R, Kreuser, Shannon A, Prieskorn, Brooke, Balcaitis, Stephanie, Davis, Amira, Ellenbogen, Richard G, Crane, Courtney A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597484/
https://www.ncbi.nlm.nih.gov/pubmed/33122397
http://dx.doi.org/10.1136/jitc-2020-001202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597484/
https://www.ncbi.nlm.nih.gov/pubmed/33122397
http://dx.doi.org/10.1136/jitc-2020-001202

Ejemplares similares